Kenvue Inc. (NYSE:KVUE) Shares Bought by Aviva PLC

Aviva PLC increased its position in Kenvue Inc. (NYSE:KVUE) by 1,159.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,154,701 shares of the company’s stock after acquiring an additional 1,063,043 shares during the period. Aviva PLC owned approximately 0.06% of Kenvue worth $24,653,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Grove Bank & Trust boosted its position in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth $29,000. SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC increased its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Down 5.5 %

Shares of KVUE opened at $22.33 on Monday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company’s fifty day moving average is $22.59 and its two-hundred day moving average is $22.46. The firm has a market cap of $42.68 billion, a PE ratio of 42.14, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analyst Ratings Changes

Several research firms have recently commented on KVUE. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Piper Sandler increased their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays lifted their price objective on Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 27th. Finally, Canaccord Genuity Group upped their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.